

REPORT RELEASE


MEMO TO: W. Waite
Supervisor, R & D Central File

COPY TO: Director of Pathology - P. H. Craig
Director of Toxicology - W. R. Pool
PSA Coordinator - S. Molinary
PSA Project Monitor - S. Molinary
Manager, Systems Coordination - M. Steffen
Director, Product Safety Assessment (France) - P. Delort
Vice President, Medical Research - K. Agre
Vice President, Corporate Medical Affairs - W. S. Smith
Regulatory Affairs - W. Merino
Director, International Medical Affairs - W. Inglis
Manager, Quality Assurance Monitoring - D. Howard
Vice President, Research & Development - P. Klimstra

FROM: G. D. Lumb

SUBJECT: Release of Report, An Evaluation of the Mutagenic Potential
of SC-18862 Employing the Ames Salmonella/Microsome Assay;
S.A. 1385.

I have reviewed the final report of the subject study from SRI International (Menlo Park, California) dated February, 1978 and approve its release and distribution.

 4/27/78

G. D. Lumb, M.D., M.R.C.P. Date
Vice President,
Product Safety Assessment
Searle Laboratories

Attachment

CID Report Document Number: PS 78C-1385A

Searle Laboratories, Skokie, IL

DEPARTMENT OF PRODUCT SAFETY ASSESSMENT

Study No. 1385

Title: An Evaluation of the Mutagenic Potential of SC-18862
Employing the Ames Salmonella/Microsome Assay

Author(s): Vincent F. Simmon and Hsin-Tsan G. Shan (SRI International)

Date: February 1978

Type of Report: Final

Abstract:

SRI International examined G. D. Searle & Co. compound SC-18862 (Lot C-0096-89300) for mutagenicity using the Ames Salmonella/microsome assay with the five tester strains TA1535, TA1537, TA1538, TA98, TA100. The assay was performed both in the presence and in the absence of a rat liver homogenate metabolic activation system.

SC-18862 was not mutagenic in the bacterial assay with S. typhimurium, neither in the presence nor in the absence of the metabolic activation system.

Informational copies of this report may be obtained from Technical Information Section, CID, Concourse 2.

Clean copies of this report to be used for regulatory submissions may be obtained from the R & D Central File, H-1.

REPORT RELEASE


MEMO TO: File, S.A. 1385

COPY TO: G. D. Lumb


FROM: S. Molinary
P. Craig

SUBJECT: Release of Report, An Evaluation of the Mutagenic Potential
of SC-18862 Employing the Ames Salmonella/Microsome Assay;
S.A. 1385.

I have reviewed the final report of the subject study from SRI International, Menlo Park, California, dated February, 1978 and approve its release and distribution.


S. Molinary
PSA Coordinator

4/25/78
Date


P. Craig
Director of Pathology

4/25/78
Date

An Evaluation of the Mutagenic Potential of SC-18862
Employing the Ames Salmonella/Microsome Assay; S. A. 1385

ERRATA

Page 1, paragraph 1, line 2, "(Lot C-00696-89300)" should be
"(Lot C-0096-89300)".

AN EVALUATION OF THE MUTAGENIC POTENTIAL OF SC-18862
EMPLOYING THE AMES SALMONELLA/MICROSOME ASSAY;
S. A. 1385

Final Report

February 1978

By: Vincent F. Simmon, Ph.D., Manager
Microbial Genetics Program
Hsin-Tsan G. Shan, Microbiologist


Prepared for:

SEARLE LABORATORIES
Division of G. D. Searle & Co.
Box 5110
Chicago, Illinois 60680


Attention: Dr. Samuel Molinary
Supervisor, Genetic Toxicology
Safety Assessment Department

SRI Project LSC-5992


Approved:



Vincent F. Simmon, Manager
Microbial Genetics Program



Gordon W. Newell, Director
Department of Toxicology



W. A. Skinner, Executive Director
Life Sciences Division



333 Ravenswood Ave. • Menlo Park, California 94025
(415) 326-6200 • Cable: STANRES, Menlo Park • TWX: 910-373-1246

SUMMARY

SRI International examined G. D. Searle & Co. compound SC-18862 (Lot C-00696-89300) for mutagenicity using the Ames Salmonella/microsome assay with the five tester strains TA1535, TA1537, TA1538, TA98, and TA100. The assay was performed both in the presence and in the absence of a rat liver homogenate metabolic activation system.

SC-18862 was not mutagenic in the bacterial assay with S. typhimurium, neither in the presence nor in the absence of the metabolic activation system.

INTRODUCTION

SRI International examined G. D. Searle & Co. compound SC-18862 (Lot C-0096-89300) for mutagenic activity by in vitro microbiological assays with five strains of Salmonella typhimurium--TA1535, TA1537, TA1538, TA98, and TA100. An Aroclor 1254-stimulated, rat liver homogenate metabolic activation system was included in the assay procedure to provide metabolic steps that the bacteria either are incapable of conducting or do not carry out under the assay conditions.

The Ames Salmonella/microsome assay has proven to be 80 to 90% reliable in detecting carcinogens as mutagens, and it has about the same reliability in identifying chemicals that are not carcinogenic.¹ However, because this system does not always provide 100% correlation with carcinogenicity investigations in animals, neither a positive nor a negative response proves conclusively that a chemical is hazardous or nonhazardous to man.

METHODS

Salmonella typhimurium Strains TA1535, TA1537, TA1538, TA98, and TA100

The Salmonella typhimurium strains used at SRI are all histidine auxotrophs by virtue of mutations in the histidine operon. When these histidine-dependent cells are grown on minimal medium petri plates containing a trace of histidine, only those cells that revert to histidine independence (his⁺) are able to form colonies. The small amount of histidine allows all the plated bacteria to undergo a few divisions; in many cases, this growth is essential for mutagenesis to occur. The his⁺ revertants are easily scored as colonies against the slight background growth. The spontaneous mutation frequency of each strain is relatively constant, but when a mutagen is added to the agar the mutation frequency is increased 2- to 100-fold.

We obtained our S. typhimurium strains from Dr. Bruce Ames of the University of California at Berkeley.¹⁻⁵ In addition to having mutations in the histidine operon, all the indicator strains have a mutation (rfa⁻) that leads to a defective lipopolysaccharide coat; they also have a deletion that covers genes involved in the synthesis of the vitamin, biotin (bio⁻), and in the repair of ultraviolet (uv)-induced DNA damage (uvrB⁻). The rfa⁻ mutation makes the strains more permeable to many large aromatic molecules, thereby increasing the mutagenic effect of these molecules. The uvrB⁻ mutation decreases repair of some types of chemically or physically damaged DNA and thereby enhances the strains' sensitivity to some mutagenic agents. Strain TA1535 is reverted to his⁺ by many mutagens that cause base-pair substitutions. TA100 is derived from TA1535 by the introduction of the resistance transfer factor plasmid pKM101. This plasmid is believed to cause an increase in error-prone DNA repair that leads to many more mutations

for a given dose of most mutagens.⁵ In addition, plasmid pKM101 confers resistance to the antibiotic ampicillin, which is a convenient marker to detect the presence of the plasmid in the cells. The presence of this plasmid also makes strain TA100 sensitive to some frameshift mutagens (e.g., ICR-191, benzo(a)pyrene, aflatoxin B₁, and 7,12-dimethylbenz(a)anthracene). Strains TA1537 and TA1538 are reverted by many frameshift mutagens. TA1537 is more sensitive than TA1538 to mutation by some acridines and benzanthraces, but the difference is quantitative rather than qualitative. Strain TA98 is derived from TA1538 by the addition of the plasmid pKM101, which makes it more sensitive to some mutagenic agents.

All indicator strains are kept at 4° C on minimal medium plates, supplemented with a trace of biotin, and an excess of histidine. The plates with the plasmid-carrying strains contain, in addition, ampicillin (25 µg/ml), to ensure stable maintenance of the plasmid pKM101. New stock culture plates are made every two months from single colony reisolates that were checked for their genotypic characteristics (his, rfa, uvrB, bio) and for the presence of the plasmid. For each experiment, an inoculum from the stock culture plates is grown overnight at 37° C in nutrient broth (Oxoid, CM67). After stationary overnight growth, the cultures are shaken for 3 to 4 hours to ensure optimal growth.

Aroclor 1254-Stimulated Metabolic Activation System

Some carcinogenic chemicals, either of the aromatic amino type or polycyclic hydrocarbon type, are inactive unless they are metabolized to active forms. In animals and man, an enzyme system in the liver or other organs (e.g., lung or kidney) is capable of metabolizing a large number of these chemicals to carcinogens.^{4,6-8} Some of these intermediate metabolites are very potent mutagens in the S. typhimurium test. Ames has described the liver metabolic activation system that we use.⁶ In brief, adult male rats (250 to 300 g) are given a single 500-mg/kg intraperitoneal injection of a polychlorinated biphenyl, Aroclor 1254. This treatment enhances the synthesis of enzymes involved in the metabolic

conversion of chemicals. Four days after the injection the animals' food is removed but drinking water is provided ad libitum. On the fifth day, the rats are killed, and the liver homogenate is prepared as follows.

The livers are removed aseptically and placed in a preweighed sterile glass beaker. The organ weight is determined, and all subsequent operations are conducted in an ice bath. The livers are washed in an equal volume of cold, sterile 0.15 M KCl (1 ml/g of wet organ), minced with sterile surgical scissors in three volumes of 0.15 M KCl, and homogenized with a Potter-Elvehjem apparatus. The homogenate is centrifuged for 10 minutes at 9000 x g, and the supernatant, referred to as the S-9 fraction, is quickly frozen in dry ice and stored at -80° C.

The metabolic activation mixture for each experiment consists of, for 10 ml:

- 1.00 ml of S-9 Fraction
- 0.20 ml of $MgCl_2$ (0.4 M) and KCl (1.65M)
- 0.05 ml of glucose-6-phosphate (1 M)
- 0.40 ml of NADP (0.1 M)
- 5.00 ml of sodium phosphate (0.2 M, pH 7.4)
- 3.35 ml of H_2O .

Assays in Agar

To a sterile 13 x 100 mm test tube placed in a 43° C heating block, we add in the following order:

- (1) 2.00 ml of 0.6% agar*
- (2) 0.05 ml of indicator organisms
- (3) 0.05 ml of a solution of the test chemical
- (4) 0.50 ml of metabolic activation mixture (optional).

For negative controls, we use steps (1), (2), and (4) (optional) and 0.05 ml of the solvent used for the test chemical. Because the majority of organic compounds are not sufficiently water soluble--particularly at the higher concentrations--we routinely use dimethylsulfoxide (DMSO). Other solvents that are occasionally used are water, ethanol, or benzene. For positive controls, we test each culture by specific mutagens known to revert each strain using steps (1), (2), (3), and (4) (optional).

This mixture is stirred gently and then poured onto minimal agar plates.[†] After the top agar has set, the plates are incubated at 37° C for 2 days. The number of his⁺ revertant colonies is counted and recorded.

* 0.6 % agar contains 0.05 mM histidine, 0.05 mM biotin, and 0.1 M NaCl.

† Minimal agar plates consist of, per liter, 15 g of agar, 10 g of glucose, 0.2 g of MgSO₄•7H₂O, 2 g of citric acid monohydrate, 10 g of K₂HPO₄, and 3.5 g of NaH₂PO₄•4H₂O.

RESULTS AND DISCUSSION

Tables 1 through 3 present the results of the microbiological assays of SC-18862 with S. typhimurium. The data in Table 1 are an average of the two assays conducted on separate days; Tables 2 and 3 present the results of the individual assays and the date they were conducted.

The compound was tested over a wide range of concentrations, from 10 to 5000 μg per plate.

Known mutagenic compounds added to the top agar of the positive control plates increase the mutation frequency from approximately 2 to over 100 times that of the background mutation frequency. When SC-18862 was added to the top agar, no reproducible, dose-related increase in mutation frequency over that of the expected background count was observed. Thus; these results lead to the conclusion that SC-18862 is not mutagenic when tested by this procedure either in the presence or in the absence of the metabolic activation system.

Table 1

IN VITRO ASSAYS WITH SALMONELLA TYPHIMURIUM - SC-18862
(LOT C-0096-89300)*

Compound	Metabolic Activation	Micrograms of Compound Added per Plate	Average Histidine Revertants per Plate			
			TA1535	TA1537	TA1538	TA100
Negative control	-		31	7	12	17
	+		27	7	21	32
Positive controls						
Sodium azide	-	1.0	174			309
9-Aminoacridine	-	100		1024		
2-Nitrofluorene	-	10			1223	934
2-Anthramine	+	2.5	166	66	876	809
SC-18862						
	-	10	28	4	12	28
	-	50	26	5	15	23
	-	100	39	8	17	22
	-	500	30	4	15	20
	-	1000	31	4	20	22
	-	5000	38	9	13	21
	+	10	25	5	25	34
	+	50	30	6	27	29
	+	100	28	7	25	24
	+	500	38	3	30	31
	+	1000	34	12	30	34
	+	5000	31	8	27	36
						117
						131
						129
						145
						146
						143
						170
						165
						157
						157
						158
						164

Table 2

IN VITRO ASSAYS WITH SALMONELLA TYPHIMURIUM - SC-18862 (LOT C-0096-89300)^a
Experiment 1 - 1/26/78

Compound	Metabolic Activation	Micrograms of Compound Added per Plate	Histidine Revertants per Plate				
			TA1535	TA1537	TA1538	TA98	TA100
Negative control	-		21	10	11	17	118
	+		11	4	22	28	104
Positive controls							
	-	1.0	174				288
	-	100		1574			
	-	10			1005	857	
2-Nitrofluorene	-	2.5	150	29	1111	866	1263
	+						
SC-18862	-	10	29	5	11	27	99
	-	50	16	4	15	23	102
	-	100	22	6	11	20	106
	-	500	16	4	12	17	114
	-	1000	15	3	19	22	107
	-	5000	21	12	18	17	84
	+	10	7	6	21	34	104
	+	50	9	8	27	29	90
	+	100	10	3	18	22	95
	+	500	16	3	27	16	94
	+	1000	17	14	26	28	94
	+	5000	10	6	31	28	107

Table 3

IN VITRO ASSAYS WITH SALMONELLA TYPHIMURIUM - SC-18862 (LOT C-0096-89300)^a
Experiment 2 - 2/5/78

Compound	Metabolic Activation	Micrograms of Compound Added per Plate	Histidine Revertants per Plate			
			TA1535	TA1537	TA1538	TA100
Negative control	-		41	5	14	17
	+		43	11	20	36
Positive controls						
	-	1.0	174			
	-	100		474		
	-	10			1441	1010
2-Nitrofluorene	+	2.5	182	102	640	752
2-Anthramine						1207
SC-18862	-	10	27	3	13	28
	-	50	36	6	15	23
	-	100	55	9	23	23
	-	500	44	4	18	23
	-	1000	47	4	21	22
	-	5000	54	5	7	25
	+	10	43	3	28	34
	+	50	51	4	27	28
	+	100	45	10	32	25
	+	500	60	3	32	46
	+	1000	50	10	33	40
	+	5000	51	10	23	43
						236
						239
						219
						220
						222
						220

REFERENCES

1. J. McCann, E. Choi, E. Yamasaki, and B. N. Ames. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. *Proc. Nat. Acad. Sci. USA* 72, 5135-5139 (1975).
2. B. N. Ames, E. G. Gurney, J. A. Miller, and H. Bartsch. Carcinogens as frameshift mutagens: Metabolites and derivatives of 2-acetylaminofluorene and other aromatic amine carcinogens. *Proc. Nat. Acad. Sci. USA* 69, 3128-3132 (1972).
3. B. N. Ames, F. D. Lee, and W. E. Durston. An improved bacterial test system for the detection and classification of mutagens and carcinogens. *Proc. Nat. Acad. Sci. USA* 70, 782-786 (1973).
4. B. N. Ames, W. E. Durston, E. Yamasaki, and F. D. Lee. Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection. *Proc. Nat. Acad. Sci. USA* 70, 2281-2285 (1973).
5. J. McCann, N. E. Spingarn, J. Kobori, and B. N. Ames. Detection of carcinogens as mutagens: Bacterial tester strains with R factor plasmids. *Proc. Nat. Acad. Sci. USA* 72, 979-983 (1975).
6. B. N. Ames, J. McCann, and E. Yamasaki. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. *Mutation Res.* 31, 347-364 (1975).
7. L. D. Kier, E. Yamasaki, and B. N. Ames. Detection of mutagenic activity in cigarette smoke condensates. *Proc. Nat. Acad. Sci. USA* 71, 4159-4163 (1974).
8. L. A. Poirier and V. F. Simmon. Mutagenic-carcinogenic relationships and the role of mutagenic screening tests for carcinogenicity. *Clin. Toxicol.* 9(5), 761-771 (1976).
9. SRI International Laboratory Notebook 2140, pp. 66 and 72.